表在性膀胱腫瘍に対する遺伝子組み換えインターロイキン2の局注効果

Abstract

表在性膀胱腫瘍12例において, rIL-2の腫瘍内局注を施行し, 腫瘍の消失を1例で, 50%以上の縮小を2例で認めた.すなわち有効率は25.0%であった.末梢血液免疫検査ではリンパ球IL-2 receptor陽性細胞の増加およびNK活性の増強を認めた.これら症例において, 軽度発熱を除き臨床上問題となる副作用はなかった

The present study was undertaken to assess the efficacy of recombinant Interleukin 2 (rIL-2: S-6820) in treatment of superficial bladder tumors. Three intratumor injections at a dose of 5 x 10(5) units/day via urethra, were performed every other day under endoscopic control in 12 patients with superficial bladder cancer. On the 15th day after completion of the series of injections, the tumor had disappeared in one patient and 50% regression over was observed in two other patients. Therefore, the response rate to the rIL-2 treatment in our study was 25.0%. Each tumor which responded to the therapy, was single, small and low grade. In the peripheral blood of the 12 patients, an increase in IL-2 receptor-positive lymphocytes and augmentation of natural killer activity were detected after the rIL-2 intratumor injection. There were no serious side effects except for moderate fever in our study.